Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ent001
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001
Details : Ent001 targets the TMEM219 ligand, IGFBP3, it is designed to bind to TMEM219 and prevent cell death and the inflammation in type 1 diabetes and several other autoimmune diseases.
Product Name : Ent001
Product Type : Antibody
Upfront Cash : Inapplicable
July 03, 2023
Lead Product(s) : Ent001
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ent001
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Roche Venture Fund
Deal Size : $42.3 million
Deal Type : Series A Financing
Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of €35m
Details : The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Enthera’s lead candidate.
Product Name : Ent001
Product Type : Antibody
Upfront Cash : Undisclosed
January 28, 2021
Lead Product(s) : Ent001
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Roche Venture Fund
Deal Size : $42.3 million
Deal Type : Series A Financing
Lead Product(s) : Ent001
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Sofinnova Partners
Deal Size : $33.1 million
Deal Type : Series A Financing
Details : Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.
Product Name : Ent001
Product Type : Antibody
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : Ent001
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Sofinnova Partners
Deal Size : $33.1 million
Deal Type : Series A Financing